MicroRNA‑145‑5p suppresses fascin to inhibit the invasion and migration of cervical carcinoma cells

He,Shufang; Yu,Guiyuan; Peng,Ke; Liu,Sisun

doi:10.3892/mmr.2020.11592

MicroRNA‑145‑5p suppresses fascin to inhibit the invasion and migration of cervical carcinoma cells

Authors:
- Shufang He
- Guiyuan Yu
- Ke Peng
- Sisun Liu
View Affiliations

Affiliations: Department of Gynecology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China
Published online on: October 14, 2020 https://doi.org/10.3892/mmr.2020.11592
Pages: 5282-5292
Copyright: © He et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRs) can affect the progression of cervical cancer (CC). The present study investigated the function of miR‑145‑5p in CC and demonstrated its association with fascin (FSCN1). The expression levels of miR‑145‑5p in CC tissues and cell lines were analyzed using reverse transcription‑quantitative PCR, and its direct targets were explored using a luciferase reporter assay. The viability, migration and invasion of HeLa cells transfected with small interfering FSCN1 or with miR‑145‑5p mimics and inhibitors were analyzed using Cell Counting Kit‑8 and Transwell assays. The expression levels of FSCN1 mRNA and protein were investigated using reverse transcription PCR and western blotting. miR‑145‑5p was downregulated in CC tissues and cell lines. Moreover, overexpression of miR‑145‑5p inhibited the migration, invasion and viability of HeLa cells. miR‑145‑5p directly targeted FSCN1, which regulated the suppressive functions of miR‑145‑5p in CC cells. Overall, miR‑145‑5p is a tumor suppressor gene and a promising target for CC treatment.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI
2	Yu Y, Zhang Y and Zhang S: MicroRNA-92 regulates cervical tumorigenesis and its expression is upregulated by human papillomavirus-16 E6 in cervical cancer cells. Oncol Lett. 6:468–474. 2013.PubMed/NCBI
3	Park TW, Fujiwara H and Wright TC: Molecular biology of cervical cancer and its precursors. Cancer. 76((10 Suppl)): S1902–S1913. 1995.
4	Peiretti M, Zapardiel I, Zanagnolo V, Landonia F, Morrowc CP and Maggionia A: Management of recurrent cervical cancer: A review of the literature. Surg Oncol. 21:e59–e66. 2012.PubMed/NCBI
5	Li N, Cui T, Guo W, Wang D and Mao L: MiR-155-5p accelerates the metastasis of cervical cancer cell via targeting TP53INP1. Onco Targets Ther. 12:3181–3196. 2019.PubMed/NCBI
6	Farazi TA, Hoell JI, Morozov P and Tuschl T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20. 2013.PubMed/NCBI
7	Pardini B, De Maria D, Francavilla A, Di Gaetano C, Ronco G and Naccarati A: MicroRNAs as markers of progression in cervical cancer: A systematic review. BMC Cancer. 18:6962018.PubMed/NCBI
8	Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, et al: MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65:7065–7070. 2005.PubMed/NCBI
9	Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et al: MicroRNA signatures in human ovarian cancer. Cancer Res. 67:8699–8707. 2007.PubMed/NCBI
10	Takagi T and Iio AY: Decreased expression of microRNA-143 and −145 in human gastric cancers. Oncology. 77:12–21. 2009.PubMed/NCBI
11	Liu X, Sempere LF, Galimberti F, Freemantle SJ, Black C, Dragnev KH, Ma Y, Fiering S, Memoli V, Li H, et al: Uncovering growth-suppressive MicroRNAs in lung cancer. Clin Cancer Res. 15:1177–1183. 2009.PubMed/NCBI
12	Li C, Xu N, Li YQ, Wang Y and Zhu ZT: Inhibition of SW620 human colon cancer cells by upregulating mi RNA-145. World J Gastroenterol. 22:2771–2778. 2016.PubMed/NCBI
13	Zhang J, Wang L, Li B, Huo M, Mu MU, Liu J and Han J: miR-145 downregulates the expression of cyclin-dependent kinase 6 in human cervical carcinoma cells. Ther Med. 8:591–594. 2014.
14	Hashimoto Y, Skacel M and Adams JC: Roles of fascin in human carcinoma motility and signaling: Prospects for a novel biomarker? Int J Biochem Cell Biol. 37:1787–804. 2005.PubMed/NCBI
15	Li A, Dawson JC, Forero-Vargas M, Spence HJ, Yu XZ, König I, Anderson K and Machesky LM: The actin-bundling protein fascin stabilizes actin in invadopodia and potentiates protrusive invasion. Curr Biol. 20:339–345. 2010.PubMed/NCBI
16	Liu R, Liao J, Yang M, Sheng J, Yang H, Wang Y, Pan E, Guo W, Pu Y, Kim SJ and Yin L: The cluster of miR-143 and miR-145 affects the risk for esophageal squamous cell carcinoma through co-regulating fascin homolog 1. PLoS One. 7:e339872012.PubMed/NCBI
17	Zhang M, Dong BB, Lu M, Zheng MJ, Chen H, Ding JZ, Xu AM and Xu YH: miR-429 functions as a tumor suppressor by targeting FSCN1 in gastric cancer cells. Onco Targets Ther. 9:1123–1133. 2016.PubMed/NCBI
18	Li J, Lu J, Ye Z, Han X, Zheng X, Hou H, Chen W, Li X and Zhao L: 20(S)-Rg3 blocked epithelial-mesenchymal transition through DNMT3A/miR-145/FSCN1 in ovarian cancer. Oncotarget. 8:53375–53386. 2017.PubMed/NCBI
19	Chen JJ, Cai WY, Liu XW, Luo QC, Chen G, Huang WF, Li N, Cai JC and Yang CF: Reverse correlation between MicroRNA-145 and FSCN1 affecting gastric cancer migration and invasion. PLoS One. 10:e0126902015.
20	Ma L and Li LL: miR-145 Contributes to the progression of cervical carcinoma by directly regulating FSCN1. Cell Transplant. 28:1299–1305. 2019.PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI
22	Bartel DP: MicroRNAs genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004.PubMed/NCBI
23	Iorio MV and Croce CM: MicroRNAs in cancer: Small molecules with a huge impact. J Clin Oncol. 27:5848–5856. 2009.PubMed/NCBI
24	Slattery ML, Herrick JS, Mullany LE, Valeri N, Stevens J, Caan BJ, Samowitz W and Wolff RK: An evaluation and replication of miRNAs with disease stage and colorectal cancer-specific mortality. Int J Cancer. 137:428–438. 2015.PubMed/NCBI
25	Gao W, Zhang C, Li W, Li H, Sang J, Zhao Q, Bo Y, Luo H, Zheng X, Lu Y, et al: Promoter methylation-regulated miR-145-5p inhibits laryngeal squamous cell carcinoma progression by targeting FSCN1. Mol Ther. 27:365–379. 2019.PubMed/NCBI
26	Stewart CJ, Crook M and Loi S: Fascin expression in endocervical neoplasia: Correlation with tumour morphology and growth pattern. J Clin Pathol. 65:213–217. 2012.PubMed/NCBI
27	Koay MH, Crook M and Stewart CJ: Fascin expression in cervical normal squamous epithelium, cervical intraepithelial neoplasia, and superficially invasive (stage IA1) squamous carcinoma of the cervix. Pathology. 46:433–438. 2018.
28	Zhao D, Zhang T, Hou XM and Ling XL: Knockdown of fascin-1 expression suppresses cell migration and invasion of non-small cell lung cancer by regulating the MAPK pathway. Biochem Biophys Res Commun. 497:694–699. 2018.PubMed/NCBI
29	Yang J, Zhang N, Gao R, Zhu Y, Zhang Z, Xu X, Wang J, Li Z, Liu X, Li Z, et al: TGF-β1 induced fascin1 expression facilitates the migration and invasion of kidney carcinoma cells through ERK and JNK signaling pathways. Biochem Biophys Res Commun. 501:913–919. 2018.PubMed/NCBI
30	Zhang M, Zhao Z, Duan X, Chen P, Peng Z and Qiu H: FSCN1 predicts survival and is regulated by a PI3K-dependent mechanism in renal cell carcinoma. J Cell Physiol. 233:4748–4758. 2018.PubMed/NCBI